| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.75 [0.66, 0.85] | | < 1 | | 55% | 7 studies (7/-) | 100.0 % | low | not evaluable | high | crucial | - |
| deaths (OS) (extension) | 0.68 [0.60, 0.78] | | < 1 | | 0% | 3 studies (3/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| progression or deaths (PFS) | 0.68 [0.56, 0.82] | | < 1 | | 64% | 4 studies (4/-) | 100.0 % | some concern | not evaluable | moderate | important | - |
| DCR | 1.17 [0.92, 1.50] | | > 1 | | 0% | 2 studies (2/-) | 90.1 % | low | not evaluable | high | non important | - |
| DOR | 0.68 [0.55, 0.85] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| objective responses (ORR) | 2.14 [1.18, 3.90] | | > 1 | | 85% | 7 studies (7/-) | 99.4 % | low | not evaluable | high | non important | - |
safety endpoints 00 |
| AE (any grade) | 2.20 [1.14, 4.25] | | < 1 | | 3% | 4 studies (4/-) | 1.0 % | low | not evaluable | high | non important | - |
| AE (grade 3-4) | 1.33 [0.69, 2.56] | | < 1 | | 90% | 4 studies (4/-) | 19.9 % | low | not evaluable | high | non important | - |
| AE leading to death (grade 5) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 2.01 [1.31, 3.07] | | < 1 | | 85% | 7 studies (7/-) | 0.1 % | low | not evaluable | high | non important | - |
| TRAE (grade 3-4) | 1.77 [0.92, 3.38] | | < 1 | | 91% | 7 studies (7/-) | 4.3 % | low | not evaluable | high | non important | - |
| TRAE leading to death (grade 5) | 1.58 [0.55, 4.50] | | < 1 | | 0% | 4 studies (4/-) | 19.9 % | low | not evaluable | high | non important | - |
| TRAE leading to discontinuation (any grade) | 1.28 [0.72, 2.27] | | < 1 | | 74% | 3 studies (3/-) | 20.2 % | some concern | not evaluable | moderate | non important | - |
| TRAE leading to discontinuation (grade 3-4) | 2.23 [1.51, 3.30] | | < 1 | | 0% | 3 studies (3/-) | 0.0 % | low | not evaluable | high | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Adrenal insufficiency TRAE (grade 3-4) | 1.43 [0.27, 7.58] | | < 1 | | 0% | 4 studies (4/-) | 33.8 % | low | not evaluable | high | non important | - |
| Colitis TRAE (grade 3-4) | 1.16 [0.41, 3.33] | | < 1 | | 77% | 7 studies (7/-) | 39.0 % | low | not evaluable | high | non important | - |
| Diarrhoea TRAE (grade 3-4) | 1.51 [0.74, 3.08] | | < 1 | | 54% | 7 studies (7/-) | 12.9 % | low | not evaluable | high | non important | - |
| Endocrine disorders TRAE (grade 3-4) | 1.55 [0.34, 6.97] | | < 1 | | 68% | 4 studies (4/-) | 28.5 % | low | not evaluable | high | non important | - |
| Eye disorders TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Febrile neutropenia TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Gastrointestinal disorders TRAE (grade 3-4) | 2.16 [0.84, 5.60] | | < 1 | | 69% | 4 studies (4/-) | 5.6 % | low | not evaluable | high | non important | - |
| Guillain-Barré syndrome TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 2.45 [0.95, 6.28] | | < 1 | | 0% | 7 studies (7/-) | 3.1 % | low | not evaluable | high | non important | - |
| Hepatobiliary disorders TRAE (grade 3-4) | 0.53 [0.15, 1.80] | | < 1 | | 0% | 3 studies (3/-) | 84.6 % | low | not evaluable | high | non important | - |
| Hypersensitivity TRAE (grade 3-4) | 6.01 [0.30, 120.38] | | < 1 | | 0% | 1 study (1/-) | 12.3 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.57 [0.07, 4.44] | | < 1 | | 0% | 3 studies (3/-) | 70.3 % | some concern | not evaluable | moderate | non important | - |
| Hypophysitis TRAE (grade 3-4) | 1.00 [0.47, 2.10] | | < 1 | | 0% | 6 studies (6/-) | 50.5 % | low | not evaluable | high | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 1.09 [0.28, 4.24] | | < 1 | | 0% | 7 studies (7/-) | 45.2 % | low | not evaluable | high | non important | - |
| Increase AST TRAE (grade 3-4) | 1.47 [0.24, 8.98] | | < 1 | | 70% | 7 studies (7/-) | 33.8 % | low | not evaluable | high | non important | - |
| Increased ALT TRAE (grade 3-4) | 2.34 [0.53, 10.34] | | < 1 | | 63% | 7 studies (7/-) | 13.2 % | low | serious | high | non important | - |
| Increased lipase level TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Maculopapular rash TRAE (grade 3-4) | 0.94 [0.15, 5.80] | | < 1 | | 0% | 3 studies (3/-) | 52.5 % | some concern | not evaluable | moderate | non important | - |
| Nervous system disorders TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Pancreatitis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Pancytopenia TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Pericarditis TRAE (grade 3-4) | 1.99 [0.07, 59.56] | | < 1 | | 0% | 1 study (1/-) | 34.8 % | NA | not evaluable | | non important | - |
| Peripheral neuropathy TRAE (grade 3-4) | 3.99 [0.18, 88.89] | | < 1 | | 0% | 1 study (1/-) | 19.4 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 1.63 [0.29, 9.28] | | < 1 | | 0% | 3 studies (3/-) | 29.0 % | some concern | not evaluable | moderate | non important | - |
| Polymyalgia Rheumatica TRAE (grade 3-4) | 0.50 [0.02, 14.85] | | < 1 | | 0% | 1 study (1/-) | 65.5 % | NA | not evaluable | | non important | - |
| Pruritic rash TRAE (grade 3-4) | 0.72 [0.08, 6.18] | | < 1 | | 0% | 3 studies (3/-) | 61.7 % | some concern | not evaluable | moderate | non important | - |
| Pruritus TRAE (grade 3-4) | 1.31 [0.41, 4.17] | | < 1 | | 0% | 7 studies (7/-) | 32.5 % | low | not evaluable | high | non important | - |
| Rash TRAE (grade 3-4) | 2.30 [0.86, 6.17] | | < 1 | | 0% | 7 studies (7/-) | 4.9 % | low | not evaluable | high | non important | - |
| Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) | 8.03 [0.42, 152.51] | | < 1 | | 0% | 1 study (1/-) | 8.5 % | NA | not evaluable | | non important | - |
| Skin and subcutaneous tissue disorders TRAE (grade 3-4) | 1.79 [0.77, 4.18] | | < 1 | | 0% | 4 studies (4/-) | 8.9 % | low | not evaluable | high | non important | - |
| Thyroiditis TRAE (grade 3-4) | 1.49 [0.11, 19.48] | | < 1 | | 0% | 2 studies (2/-) | 38.1 % | low | not evaluable | high | non important | - |
| Uveitis TRAE (grade 3-4) | 0.72 [0.08, 6.18] | | < 1 | | 0% | 3 studies (3/-) | 61.7 % | some concern | not evaluable | moderate | non important | - |
| Vitiligo TRAE (grade 3-4) | 0.49 [0.05, 4.76] | | < 1 | | 0% | 3 studies (3/-) | 72.8 % | low | not evaluable | high | non important | - |
AE (grade 3-4) endpoints 00 |
| Abdominal pain AE (grade 3-4) | 0.40 [0.20, 0.79] | | < 1 | | 0% | 4 studies (4/-) | 99.6 % | low | not evaluable | high | non important | - |
| Anaemia AE (grade 3-4) | 0.44 [0.23, 0.84] | | < 1 | | 12% | 3 studies (3/-) | 99.3 % | low | not evaluable | high | non important | - |
| Asthenia AE (grade 3-4) | 0.17 [0.02, 1.39] | | < 1 | | 0% | 1 study (1/-) | 95.0 % | NA | not evaluable | | non important | - |
| Chills AE (grade 3-4) | 1.02 [0.02, 51.42] | | < 1 | | 0% | 1 study (1/-) | 49.7 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 0.80 [0.27, 2.38] | | < 1 | | 0% | 4 studies (4/-) | 65.8 % | low | not evaluable | high | non important | - |
| Cough AE (grade 3-4) | 0.99 [0.17, 5.76] | | < 1 | | 0% | 4 studies (4/-) | 50.2 % | low | not evaluable | high | non important | - |
| Decreased appetite AE (grade 3-4) | 0.65 [0.31, 1.39] | | < 1 | | 0% | 4 studies (4/-) | 86.6 % | low | not evaluable | high | non important | - |
| Diarrhoea AE (grade 3-4) | 3.93 [0.81, 19.19] | | < 1 | | 66% | 4 studies (4/-) | 4.6 % | low | not evaluable | high | non important | - |
| Dyspnoea AE (grade 3-4) | 1.03 [0.50, 2.13] | | < 1 | | 25% | 4 studies (4/-) | 46.5 % | low | not evaluable | high | non important | - |
| Fatigue AE (grade 3-4) | 1.58 [0.84, 2.97] | | < 1 | | 46% | 4 studies (4/-) | 7.6 % | low | not evaluable | high | non important | - |
| Headache AE (grade 3-4) | 0.78 [0.33, 1.84] | | < 1 | | 8% | 4 studies (4/-) | 71.8 % | low | not evaluable | high | non important | - |
| Increase AST AE (grade 3-4) | 18.42 [5.64, 60.14] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 34.83 [8.39, 144.67] | | < 1 | | 0% | 1 study (1/-) | 0.0 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.88 [0.42, 1.83] | | < 1 | | 0% | 4 studies (4/-) | 63.8 % | low | not evaluable | high | non important | - |
| Pruritus AE (grade 3-4) | 10.35 [0.56, 190.49] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 0.48 [0.12, 1.91] | | < 1 | | 0% | 4 studies (4/-) | 84.9 % | low | not evaluable | high | non important | - |
| Rash AE (grade 3-4) | 6.16 [0.31, 123.62] | | < 1 | | 0% | 1 study (1/-) | 12.0 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 1.13 [0.57, 2.24] | | < 1 | | 0% | 4 studies (4/-) | 36.2 % | low | not evaluable | high | non important | - |
| Weight decreased AE (grade 3-4) | 1.02 [0.06, 16.34] | | < 1 | | 0% | 1 study (1/-) | 49.6 % | NA | not evaluable | | non important | - |
